Azithromycin and survival in Streptococcus pneumoniae pneumonia: a retrospective study

被引:14
|
作者
Shorr, Andrew F. [1 ]
Zilberberg, Marya D. [2 ,3 ]
Kan, Jason [4 ]
Hoffman, Justin [4 ]
Micek, Scott T. [4 ]
Kollef, Marin H. [5 ]
机构
[1] Washington Hosp Ctr, Pulm & Crit Care Med Div, Washington, DC 20010 USA
[2] EviMed Res Grp LLC, Goshen, MA USA
[3] Univ Massachusetts, Amherst, MA 01003 USA
[4] Jewish Hosp St Louis, Dept Pharm Barnes, St Louis, MO 63110 USA
[5] Washington Univ, Sch Med, Div Pulm & Crit Care Med, St Louis, MO USA
来源
BMJ OPEN | 2013年 / 3卷 / 06期
关键词
COMMUNITY-ACQUIRED PNEUMONIA; RESISTANT PATHOGENS; MACROLIDES; INTERLEUKIN-8; EPIDEMIOLOGY; VALIDATION; OUTCOMES; RISK;
D O I
10.1136/bmjopen-2013-002898
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Streptococcus pneumoniae (SP) represents a major pathogen in pneumonia. The impact of azithromycin on mortality in SP pneumonia remains unclear. Recent safety concerns regarding azithromycin have raised alarm about this agent's role with pneumonia. We sought to clarify the relationship between survival and azithromycin use in SP pneumonia. Design: Retrospective cohort. Setting: Urban academic hospital. Participants: Adults with a diagnosis of SP pneumonia (January-December 2010). The diagnosis of pneumonia required a compatible clinical syndrome and radiographic evidence of an infiltrate. Intervention: None. Primary and secondary outcome measures: Hospital mortality served as the primary endpoint, and we compared patients given azithromycin with those not treated with this. Covariates of interest included demographics, severity of illness, comorbidities and infection-related characteristics (eg, appropriateness of initial treatment, bacteraemia). We employed logistic regression to assess the independent impact of azithromycin on hospital mortality. Results: The cohort included 187 patients (mean age: 67.0 +/- 8.2 years, 50.3% men, 5.9% admitted to the intensive care unit). The most frequently utilised non-macrolide antibiotics included: ceftriaxone (n=111), cefepime (n=31) and moxifloxacin (n=22). Approximately two-thirds of the cohort received azithromycin. Crude mortality was lower in persons given azithromycin (5.6% vs 23.6%, p<0.01). The final survival model included four variables: age, need for mechanical ventilation, initial appropriate therapy and azithromycin use. The adjusted OR for mortality associated with azithromycin equalled 0.26 (95% CI 0.08 to 0.80, p=0.018). Conclusions: SP pneumonia generally remains associated with substantial mortality while azithromycin treatment is associated with significantly higher survival rates. The impact of azithromycin is independent of multiple potential confounders.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Roentgenographic findings of pneumonia caused by Chlamydia pneumoniae - Comparison with Streptococcus pneumonia
    Kauppinen, MT
    Lahde, S
    Syrjala, H
    ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (16) : 1851 - 1856
  • [42] Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae
    Bergman, Miika
    Huikko, Solja
    Huovinen, Pentti
    Paakkari, Pirkko
    Seppala, Helena
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (11) : 3646 - 3650
  • [43] Pneumonia Due to Drug-Resistant Streptococcus pneumoniae
    Jinno, Sadao
    Jacobs, Michael R.
    CURRENT INFECTIOUS DISEASE REPORTS, 2012, 14 (03) : 292 - 299
  • [44] A role for Streptococcus pneumoniae in virus-associated pneumonia
    Shabir A Madhi
    Keith P Klugman
    Nature Medicine, 2004, 10 : 811 - 813
  • [45] Mixed bacteremic pneumonia by Streptococcus pneumoniae and Haemophilus influenzae
    Oteo, J
    Alós, JI
    Gómez-Garcés, JL
    CLINICAL MICROBIOLOGY AND INFECTION, 2001, 7 (10) : 571 - 571
  • [46] Benign Purpura Secondary to Streptococcus pneumoniae Associated Pneumonia
    Sarikaya, Rukiye I. N. A. N.
    Karasahin, Omer
    FLORA INFEKSIYON HASTALIKLARI VE KLINIK MIKROBIYOLOJI DERGISI, 2023, 28 (03): : 569 - 574
  • [47] A role for Streptococcus pneumoniae in virus-associated pneumonia
    Madhi, SA
    Klugman, KP
    NATURE MEDICINE, 2004, 10 (08) : 811 - 813
  • [48] Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia
    File, TM
    CLINICAL MICROBIOLOGY AND INFECTION, 2006, 12 : 31 - 41
  • [49] SEVERE NECROTIZING PNEUMONIA WITH BACTEREMIA FROM STREPTOCOCCUS PNEUMONIAE
    Steadman, Azin
    Williams, Ruth
    Charnvitayapong, Panida
    CHEST, 2024, 166 (04) : 4472A - 4473A
  • [50] The Role of Streptococcus pneumoniae in Community-Acquired Pneumonia
    Feldman, Charles
    Anderson, Ronald
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 37 (06) : 806 - 818